149 related articles for article (PubMed ID: 17598974)
1. Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population.
Erdogan M; Karadeniz M; Berdeli A; Tamsel S; Ertan Y; Uluer H; Yilmaz C; Tuzun M; Kabalak T; Ozgen AG
J Endocrinol Invest; 2007 May; 30(5):411-6. PubMed ID: 17598974
[TBL] [Abstract][Full Text] [Related]
2. Fas/FasL gene polymorphism in patients with Hashimoto's thyroiditis in Turkish population.
Erdogan M; Kulaksizoglu M; Ganidagli S; Berdeli A
J Endocrinol Invest; 2017 Jan; 40(1):77-82. PubMed ID: 27572459
[TBL] [Abstract][Full Text] [Related]
3. Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population.
Verim L; Timirci-Kahraman O; Akbulut H; Akbas A; Ozturk T; Turan S; Yaylim I; Ergen A; Ozturk O; Isbir T
In Vivo; 2014; 28(3):397-402. PubMed ID: 24815844
[TBL] [Abstract][Full Text] [Related]
4. Single nucleotide polymorphisms of the Fas gene are associated with papillary thyroid cancer.
Eun YG; Lee YC; Kim SK; Chung JH; Kwon KH; Park IS
Auris Nasus Larynx; 2015 Aug; 42(4):326-31. PubMed ID: 25824544
[TBL] [Abstract][Full Text] [Related]
5. Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis.
Kobak Ş; Berdeli A
Reumatismo; 2012 Dec; 64(6):374-9. PubMed ID: 23285481
[TBL] [Abstract][Full Text] [Related]
6. [Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer].
Yang S; Miao XP; Zhang XM; Sun T; Qu SN; Xiong P; Ye YJ; Guo YL; Tan W; Wang S; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2132-5. PubMed ID: 16313826
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population.
Erdogan M; Karadeniz M; Ozbek M; Ozgen AG; Berdeli A
J Endocrinol Invest; 2008 Sep; 31(9):750-4. PubMed ID: 18997484
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of death pathway genes FAS and FASL polymorphisms in chronic HBV infection.
Zamani AG; Barlas IO; Durakbasi-Dursun G; Ural O; Erdal E; Yildirim MS
Int J Immunogenet; 2013 Dec; 40(6):482-7. PubMed ID: 23560484
[TBL] [Abstract][Full Text] [Related]
9. Association between FAS and FASL genetic variants and risk of primary brain tumor.
Dalan AB; Timirci-Kahraman O; Turan S; Kafadar AM; Yaylim I; Ergen A; Gormus U; Gulec-Yilmaz S; Kaspar C; Isbir T
Int J Neurosci; 2014 Jun; 124(6):443-9. PubMed ID: 24094130
[TBL] [Abstract][Full Text] [Related]
10. Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
Edathara PM; Gorre M; Kagita S; Vuree S; Cingeetham A; Nanchari SR; Meka PB; Annamaneni S; Digumarthi RR; Satti V
Tumour Biol; 2016 Apr; 37(4):5475-84. PubMed ID: 26563376
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
Zhou RM; Wang N; Chen ZF; Duan YN; Sun DL; Li Y
J Gastroenterol Hepatol; 2010 Mar; 25(3):555-61. PubMed ID: 20074157
[TBL] [Abstract][Full Text] [Related]
12. MMP-9-1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression.
Roncevic J; Djoric I; Selemetjev S; Jankovic J; Dencic TI; Bozic V; Cvejic D
Pathology; 2019 Jan; 51(1):55-61. PubMed ID: 30497805
[TBL] [Abstract][Full Text] [Related]
13. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.
Daripally S; Nallapalle SR; Katta S; Prasad VV
Tumour Biol; 2015 Sep; 36(10):7817-30. PubMed ID: 25944167
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population.
Wang LH; Ting SC; Chen CH; Tsai CC; Lung O; Liu TC; Lee CW; Wang YY; Tsai CL; Lin YC
J Oral Pathol Med; 2010 Feb; 39(2):155-61. PubMed ID: 20359312
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma.
Cao Y; Miao XP; Huang MY; Deng L; Lin DX; Zeng YX; Shao JY
Mol Carcinog; 2010 Nov; 49(11):944-50. PubMed ID: 20842669
[TBL] [Abstract][Full Text] [Related]
17. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer.
Zhang X; Miao X; Sun T; Tan W; Qu S; Xiong P; Zhou Y; Lin D
J Med Genet; 2005 Jun; 42(6):479-84. PubMed ID: 15937082
[TBL] [Abstract][Full Text] [Related]
18. FAS -670 A/G polymorphism may be associated with the depletion of CD4(+) T lymphocytes in HIV-1 infection.
Hermes RB; Santana BB; Lima SS; Neris Martins Feitosa R; de Oliveira Guimarães Ishak M; Ishak R; Vallinoto AC
Hum Immunol; 2015 Oct; 76(10):742-6. PubMed ID: 26429326
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of extrinsic death receptor apoptotic genes (FAS -670 G>A, FASL -844 T>C) in coronary artery disease.
Kishore Kumar G; Rajesh Kumar G; Mrudula Spurthi K; Nivas S; Chiranjeevi P; Ali A; Sahu SK; Pratibha N; Surekha Rani H
Apoptosis; 2016 May; 21(5):558-65. PubMed ID: 26922070
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of apoptosis-related genes: Fas (CD94), FasL (CD178) and TRAIL polymorphisms in Iranian multiple sclerosis patients.
Mohammadzadeh A; Pourfathollah AA; Sahraian MA; Behmanesh M; Daneshmandi S; Moeinfar Z; Heidari M
J Neurol Sci; 2012 Jan; 312(1-2):166-9. PubMed ID: 21864851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
